Johnson & Johnson $JNJ Shares Acquired by WealthPlan Investment Management LLC

Key Points

• WealthPlan Investment Management LLC increased its stake in Johnson & Johnson by 20.2% in the second quarter, owning a total of 70,070 shares worth approximately $10.7 million.
• Analysts have raised their price targets for Johnson & Johnson, with HSBC leading the way by adjusting its target from $188 to $210, reflecting strong institutional support with over 69.55% of the stock held by investors.
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, with the dividend yield standing at 2.7%, indicating ongoing financial health amidst recent changes in stock ownership.

WealthPlan Investment Management LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 20.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 70,070 shares of the company's stock after purchasing an additional 11,759 shares during the period. WealthPlan Investment Management LLC's holdings in Johnson & Johnson were worth $10,703,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Apexium Financial LP boosted its holdings in shares of Johnson & Johnson by 10.7% during the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company's stock worth $3,978,000 after purchasing an additional 2,310 shares during the last quarter. Avanza Fonder AB raised its position in shares of Johnson & Johnson by 2.9% during the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company's stock valued at $35,842,000 after buying an additional 6,566 shares during the period. Joel Isaacson & Co. LLC raised its position in shares of Johnson & Johnson by 3.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock valued at $12,294,000 after buying an additional 2,526 shares during the period. Tokio Marine Asset Management Co. Ltd. raised its position in shares of Johnson & Johnson by 7.0% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company's stock valued at $12,164,000 after buying an additional 4,816 shares during the period. Finally, Absher Wealth Management LLC raised its position in shares of Johnson & Johnson by 1.2% during the 1st quarter. Absher Wealth Management LLC now owns 215,584 shares of the company's stock valued at $35,752,000 after buying an additional 2,469 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

JNJ has been the topic of several analyst reports. Morgan Stanley set a $190.00 price target on shares of Johnson & Johnson in a research report on Wednesday. HSBC lifted their price target on shares of Johnson & Johnson from $188.00 to $210.00 in a research report on Tuesday, September 30th. Barclays lifted their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Sanford C. Bernstein boosted their target price on Johnson & Johnson from $172.00 to $193.00 and gave the company a "market perform" rating in a research report on Monday, October 6th. Finally, Bank of America boosted their target price on Johnson & Johnson from $198.00 to $204.00 and gave the company a "neutral" rating in a research report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $199.59.

Johnson & Johnson Stock Up 0.6%

Shares of NYSE JNJ opened at $193.27 on Friday. The firm has a market cap of $465.45 billion, a price-to-earnings ratio of 18.65, a PEG ratio of 2.26 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $194.40. The business's 50 day moving average is $180.49 and its two-hundred day moving average is $164.80.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%.The company had revenue of $24.02 billion for the quarter. Research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson's dividend payout ratio is 55.61%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.